OAKLAND PARK, FL--(Marketwired - Mar 24, 2017) - BioStem Technologies, Inc. (
The facility is a showcase of quality that will enable BSEM to leverage its vertical integration strategy in the Health, Wellness and Biotechnology sectors. The lab will serve as the Quality, R&D, and Pharmaceutical Manufacturing Laboratory, not only for the Company's in-house operations, but also for its contract formulation and contract manufacturing services. The Company is in the process of finalizing its certifications for the ISO 8, 7, and 5 suites, as well as validation of the cGMP and cGLP areas. Corporate operations are expected to move to the new facility in Q2 2017, while the operations of Qualified Pharma Ingredients, one of the company's subsidiaries, will remain at its current location in Oakland Park, Florida.
About BioStem Technologies, Inc. (
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
Contact Information:
BioStem Technologies, Inc.:
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
Andrew Van Vurst
info@biostemtech.com
954.380.8342